Strategic partnerships Vanqua Bio is actively expanding through collaborations with Ardena Holding NV and CHDR to advance its brain-penetrant GCase activator VQ-101 in Phase 1 studies, signaling readiness for co-development opportunities and early-access deals with CROs and biotech partners.

Clinical program scale With a clinical-stage focus and ongoing presentations at major neurology conferences (AD/PD 2026, World Parkinson’s Congress, GBA1 Meeting), there are high-visibility milestones to anchor discussions around licensing, co-development, or milestone-based value-sharing arrangements.

Genetics-driven focus Vanqua Bio leverages human genetics to identify disease-causing or risk-raising genes in neurodegeneration, presenting a compelling rationale for collaborations with academic centers, gene-targeting platforms, and biomarker validation partners.

Resource readiness The company’s proprietary in vitro patient-derived neuronal models and focus on CNS-penetrant modalities suggest opportunities to offer specialized contract research, preclinical services, or model licensing to larger pharmaceutical players seeking neuroscience assets.

Financial leverage With funding around the mid hundreds of millions and revenue in the tens of millions, Vanqua Bio appears poised for co-funding or milestone-rich deals to accelerate clinical programs, especially with partners able to de-risk late-stage development.